Alnylam stock price target maintained at $460 by BofA Securities

Key event: BofA reiterates Buy on Alnylam with a $460 price target; company market cap $40.85B and shares are down 23% YTD despite 65% LTM revenue growth. Alnylam increased the ATTR-CM patient estimate to >500,000 globally (from ~300,000) with ~80% untreated, expects diagnosis rates up to ~70% and ~75,000 patients treated by 2030, and analysts project EPS of $9.69 in fiscal 2026; partnerships with Viz.ai, the AHA and Tenaya (up to $10M upfront) target earlier diagnosis and R&D. Valuation notes: P/E 132, PEG 0.62 and InvestingPro flags slight overvaluation; analyst views mixed (Morgan Stanley EQW $360 PT, Jefferies downgraded to Hold $330) and CEO granted 55,373 performance share units (~$18M) vesting on stock targets by end-2029.

Analysis

The revenue upside being priced into ALNY is increasingly a function of diagnosis and treatment conversion curves, not just molecule efficacy. If screening sensitivity/specificity improvements and referral pathways shorten time-to-treatment, the realized patient conversion curve could move from a multi-year slope to a 12–36 month step-function — which would materially front-load cashflows but also expose the company to accelerated payer scrutiny and prior‑authorization friction.

AI-enabled case-finding is a force-multiplier for demand generation, but it shifts the bottleneck from discovery to downstream capacity: specialty pharmacies, infusion/administration sites, and cardiac clinics. Vendors that standardize EHR data and integrate into workflows (and their reimbursement capture models) will extract margin; conversely, a high false-positive rate could trigger utilization management that reduces realized ARPU per diagnosed patient.

Valuation embeds a binary execution path over the next 3–5 years: either diagnosis and conversion scale quickly and the multiple compresses into growth, or slower uptake and payer pushback create deep downside. Management incentives tied to share-price milestones raise the odds of aggressive commercial spend or bolt-on deals to hit thresholds — both increase near-term cash burn and dilution risk if milestones aren’t met on schedule.

Key Decisions for Investors

• Long ALNY via a defined-risk call spread (ticker: ALNY). Buy a 12–18 month at-the-money call and sell a 25–35% out-of-the-money call to fund it; position size ~1.5–2% NAV. Rationale: captures upside if diagnosis/conversion accelerates over 12–24 months while limiting premium drain. Target payoff 2.5–4x premium; max loss = premium paid.
• Protective collar if long stock (ticker: ALNY). For holders looking to keep exposure, sell 6–12 month covered calls at ~20% OTM and buy 6–12 month puts ~15–20% OTM to cap downside; cost-neutral or small net credit. Use this to crystallize a 12–18 month view while funding downside protection from near-term implied volatility.
• Small asymmetric/option lottery on Tenaya (ticker: TNYA). Buy 18–24 month out-of-the-money calls or a long-dated small equity stake sized ~0.25–0.5% NAV to play upstream genetic target validation. Rationale: Skewed payoff if research collaborations yield high-value targets; accept binary total-loss risk for >5x upside.
• Tail hedge: buy deep OTM ALNY puts (ticker: ALNY) with 6–12 month expiries sized ~0.5–1% NAV. Rationale: protects against payer/reimbursement shock or diagnostic program failure; aim for >5x payoff in event of sharp re-rating. Trim if put premium falls by 60% or if ALNY outperforms and implied vol normalizes.